{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:48Z","timestamp":1789958808275,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/leu.2015.152","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T07:15:11Z","timestamp":1434698111000},"page":"1823-1831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib"],"prefix":"10.1038","volume":"29","author":[{"given":"F","family":"Castagnetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Levato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Intermesoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Pregno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Gherlinzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cavazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Venturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the GIMEMA CML Working Party","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,19]]},"reference":[{"key":"BFleu2015152_CR1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2015152_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular response to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1421\u20131432.","journal-title":"N Engl J Med"},{"key":"BFleu2015152_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2015152_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400\u2009mg versus 800\u2009mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424\u2013430.","journal-title":"J Clin Oncol"},{"key":"BFleu2015152_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2015152_CR7","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2015152_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadlephia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841\u2013851.","journal-title":"Lancet Oncol"},{"key":"BFleu2015152_CR9","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123\u20131129.","journal-title":"Blood"},{"key":"BFleu2015152_CR11","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486\u20133492.","journal-title":"J Clin Oncol"},{"key":"BFleu2015152_CR12","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analsys. J Clin Oncol 2008; 26: 3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"BFleu2015152_CR13","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","volume":"113","author":"F Castagnetti","year":"2009","unstructured":"Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S et al. Results of high dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase. A phase II trial of the GIMEMA CML working party. Blood 2009; 113: 3428\u20133434.","journal-title":"Blood"},{"key":"BFleu2015152_CR14","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E et al. Comparison of imatinib 400\u2009mg and 800\u2009mg daily in the first-line treatment of high risk, Philadelphia-positive, chronic myeloid leukemia. An European LeukemiaNet Study. Blood 2009; 113: 4497\u20134504.","journal-title":"Blood"},{"key":"BFleu2015152_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","volume":"95","author":"F Cervantes","year":"2010","unstructured":"Cervantes F, L\u00f3pez-Garrido P, Montero MI, Jonte F, Mart\u00ednez J, Hern\u00e1ndez-Boluda JC et al. Early intervention during imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010; 95: 1317\u20131324.","journal-title":"Haematologica"},{"key":"BFleu2015152_CR16","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus Peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511\u20132521.","journal-title":"N Engl J Med"},{"key":"BFleu2015152_CR17","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, M\u00fcller MC, Pletsch N et al. Tolerability-adapted imatinib 800\u2009mg\/d versus 400\u2009mg\/d versus 400\u2009mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu2015152_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0609.2011.01637.x","volume":"87","author":"E Faber","year":"2011","unstructured":"Faber E, Mu\u017e\u00edk J, Koza V, Deme\u010dkov\u00e1 E, Voglov\u00e1 J, Demitrovi\u010dov\u00e1 L et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000\u2014a report from the population-based CAMELIA registry. Eur J Haematol 2011; 87: 157\u2013168.","journal-title":"Eur J Haematol"},{"key":"BFleu2015152_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12185-012-1093-y","volume":"96","author":"D Kim","year":"2012","unstructured":"Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendations. Intern J Hematol 2012; 96: 47\u201357.","journal-title":"Intern J Hematol"},{"key":"BFleu2015152_CR20","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G et al. A randomized trial of dasatinib 100\u2009mg versus imatinib 400\u2009mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012; 120: 3898\u20133905.","journal-title":"Blood"},{"key":"BFleu2015152_CR21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffmann","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016\u20132022.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M et al. Tyrosine kinase inhibitors usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFleu2015152_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2013.095158","volume":"99","author":"G Etienne","year":"2014","unstructured":"Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A et al. Achieving deeper molecular response is associated with a better clinical out come in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica 2014; 99: 458\u2013464.","journal-title":"Haematologica"},{"key":"BFleu2015152_CR24","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood 2011; 117: 5591\u20135599.","journal-title":"Blood"},{"key":"BFleu2015152_CR25","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Foroni L et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758\u20133765.","journal-title":"Blood"},{"key":"BFleu2015152_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232\u2013238.","journal-title":"J Clin Oncol"},{"key":"BFleu2015152_CR27","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia. Leukemia 2012; 26: 2096\u20132102.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR28","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early interventions strategies. Blood 2013; 121: 2739\u20132742.","journal-title":"Blood"},{"key":"BFleu2015152_CR29","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantrajian H, Nazha A, O'Brien S, Jabbour E, Romo CG et al. Early responses predict better outcomes in patients with newly diagnoses chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013; 121: 4867\u20134874.","journal-title":"Blood"},{"key":"BFleu2015152_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2013","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study 4. J Clin Oncol 2013; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFleu2015152_CR31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353\u20131360.","journal-title":"Blood"},{"key":"BFleu2015152_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494\u2013500.","journal-title":"Blood"},{"key":"BFleu2015152_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al. Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BC R-ABL1 decline. Blood 2014; 124: 511\u2013518.","journal-title":"Blood"},{"key":"BFleu2015152_CR34","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al. Velocity of early BCR-ABL transcript elimination as an optimal predictor of outcome in chronic myeloid leukemia patients in chronic phase on treatment with imatinib. Leukemia 2014; 28: 1988\u20131992.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR35","doi-asserted-by":"crossref","unstructured":"Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood 2009; 114: abstract 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"BFleu2015152_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123\u20131132.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/leu.2011.217","volume":"26","author":"PJ Shami","year":"2012","unstructured":"Shami PJ, Deininger M . Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214\u2013224.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.2012.063172","volume":"98","author":"R Gurion","year":"2013","unstructured":"Gurion R, Gafter-Gvili A, Vidal L, Leader A, Ram R, Shacham-Abulafia A et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 2013; 98: 95\u2013102.","journal-title":"Haematologica"},{"key":"BFleu2015152_CR39","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"12","author":"Experts in Chronic Myeloid Leukemia","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 12: 4439\u20134442.","journal-title":"Blood"},{"key":"BFleu2015152_CR40","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","volume":"11","author":"S O'Brien","year":"2013","unstructured":"O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E et al. National comprehensive cancer network. Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw 2013; 11: 1327\u20131340.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFleu2015152_CR41","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2015152_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","volume":"2013","author":"T Hughes","year":"2013","unstructured":"Hughes T, White D . Which TKI? An embarassement of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program 2013; 2013: 168\u2013175.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2015152_CR43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789\u2013799.","journal-title":"Blood"},{"key":"BFleu2015152_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850\u2013858.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2015152_CR45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu2015152_CR46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999\u20131003.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649\u2013655.","journal-title":"Am J Clin Oncol"},{"key":"BFleu2015152_CR48","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meyer P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013465.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2015152_CR49","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/leu.2011.116","volume":"25","author":"M Pfirrmann","year":"2011","unstructured":"Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J . Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433\u20131438.","journal-title":"Leukemia"},{"key":"BFleu2015152_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competiting risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFleu2015152_CR51","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFleu2015152_CR52","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","volume":"119","author":"J Guilhot","year":"2012","unstructured":"Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012; 119: 5963\u20135971.","journal-title":"Blood"},{"key":"BFleu2015152_CR53","doi-asserted-by":"crossref","unstructured":"Hoffmann VS, Lindoerfer D, Pfirrmann M, Saussele S, Hochhaus A, Engel J et al. CML patients in clinical trials represent fairly well the general population of CML patients: a comparative analysis of 5803 patients from the EUTOS registry. Blood 2013; 122: abstract 2735.","DOI":"10.1182\/blood.V122.21.2735.2735"},{"key":"BFleu2015152_CR54","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood-2013-11-539742","volume":"123","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CML Study Group. The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 2014; 123: 2494\u20132496.","journal-title":"Blood"},{"key":"BFleu2015152_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-study IV. Blood 2015; 126: 42\u201349.","journal-title":"Blood"},{"key":"BFleu2015152_CR56","first-page":"256","volume":"88","author":"G Rosti","year":"2003","unstructured":"Rosti G, Trabacchi E, Bassi S, Bonifazi F, de Vivo A, Martinelli G et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003; 88: 256\u2013259.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:25:18Z","timestamp":1648743918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFleu2015152"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.152","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,19]]},"assertion":[{"value":"22 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FC has acted as a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and ARIAD; GG has acted as a consultant and received honoraria from Novartis and Bristol-Myers Squibb; M Breccia has acted as a consultant for Bristol-Myers Squibb and Novartis, Pfizer, Ariad; EA has acted as a consultant for Novartis and Bristol-Myers Squibb; GM served on the speakers\u2019 bureaus of Novartis, Bristol-Myers Squibb and Pfizer; GR has acted as a consultant for and received honoraria from Novartis; FP received research support from Novartis, served as advisor for Novartis, Bristol-Myers Squibb and ARIAD Pharmaceuticals, and received lecture fees from Novartis and Bristol-Myers Squibb; GS has acted as a consultant for and received honoraria from Bristol-Myers Squibb, Novartis, ARIAD Pharmaceuticals and Celgene; G Rosti has acted as a consultant for Novartis, Bristol-Myers Squibb and ARIAD Pharmaceuticals and served on the speakers\u2019 bureaus of Novartis, Bristol-Myers Squibb and Roche; M Baccarani received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and ARIAD Pharmaceuticals and served on the speakers\u2019 bureaus of Novartis and Bristol-Myers Squibb. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}